Efficacy and pharmacodynamics of voriconazole combined with anidulafungin in azole-resistant invasive aspergillosis

Journal of Antimicrobial Chemotherapy

Volumn 68, Issue 2, 2013, Pages 385-393

  Seyedmousavi, Seyedmojtaba ^a   Brüggemann, Roger J M ^a   Melchers, Willem J G ^a   Rijs, Antonius J M M ^a   Verweij, Paul E ^a   Mouton, Johan W ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Additivity; Azoles; Combination therapy; Echinocandins; Synergy

Indexed keywords

ANIDULAFUNGIN; VORICONAZOLE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; AREA UNDER THE CURVE; ARTICLE; ASPERGILLOSIS; ASPERGILLUS FUMIGATUS; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG CLEARANCE; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG POTENTIATION; FEMALE; FUNGAL STRAIN; MAXIMUM PLASMA CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; MOUSE; NONHUMAN; SURVIVAL; TIME TO MAXIMUM PLASMA CONCENTRATION;

ANIMALS; ANTIFUNGAL AGENTS; ASPERGILLOSIS; ASPERGILLUS FUMIGATUS; DISEASE MODELS, ANIMAL; DRUG RESISTANCE, FUNGAL; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; ECHINOCANDINS; FEMALE; MICE; PYRIMIDINES; SURVIVAL ANALYSIS; TREATMENT OUTCOME; TRIAZOLES;

EID: 84872011467     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dks402     Document Type: Article

References (46)

1. MeerssemanW, Vandecasteele SJ, Wilmer A et al. Invasive aspergillosis in critically ill patients without malignancy. Am J Respir Crit Care Med 2004; 170: 621-5.
2. Denning DW. Therapeutic outcome in invasive aspergillosis. Clin Infect Dis 1996; 23: 608-15.
3. Marr KA, Patterson T, Denning D. Aspergillosis. Pathogenesis, clinical manifestations, and therapy. Infect Dis Clin North Am 2002; 16: 875-94, vi.
4. Herbrecht R, Denning DW, Patterson TF et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002; 347: 408-15.
5. Walsh TJ, Anaissie EJ, Denning DW et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 2008; 46: 327-60.
6. Verweij PE, Howard SJ, Melchers WJ et al. Azole-resistance in Aspergillus: proposed nomenclature and breakpoints. Drug Resist Updat 2009; 12: 141-7.
7. Snelders E, van der Lee HA, Kuijpers J et al. Emergence of azole resistance in Aspergillus fumigatus and spread of a single resistance mechanism. PLoS Med 2008; 5: e219.
8. van der Linden JW, Snelders E, Kampinga GA et al. Clinical implications of azole resistance in Aspergillus fumigatus, the Netherlands, 2007-2009. Emerg Infect Dis 2011; 17: 1846-54.
9. Lockhart SR, Frade JP, Etienne KA et al. Azole resistance in Aspergillus fumigatus isolates from the ARTEMIS global surveillance study is primarily due to the TR/L98H mutation in the cyp51A gene. Antimicrob Agents Chemother 2011; 55: 4465-8.
10. Chowdhary A, Kathuria S, Randhawa HS et al. Isolation of multiple-triazole-resistant Aspergillus fumigatus strains carrying the TR/ L98H mutations in the cyp51A gene in India. J Antimicrob Chemother 2012; 67: 362-6.
11. Tashiro M, Izumikawa K, Minematsu A et al. Antifungal susceptibilities of Aspergillus fumigatus clinical isolates in Nagasaki, Japan. Antimicrob Agents Chemother 2011; 56: 584-7.
12. Verweij PE, Mellado E, Melchers WJ. Multiple-triazole-resistant aspergillosis. N Engl J Med 2007; 356: 1481-3.
13. Howard SJ, Webster I, Moore CB et al. Multi-azole resistance in Aspergillus fumigatus. Int J Antimicrob Agents 2006; 28: 450-3.
14. Mavridou E, Bruggemann RJ, MelchersWJ et al. Efficacy of posaconazole against three clinical Aspergillus fumigatus isolates with mutations in the cyp51A gene. Antimicrob Agents Chemother 2010; 54: 860-5.
15. Howard SJ, Lestner JM, Sharp A et al. Pharmacokinetics and pharmacodynamics of posaconazole for invasive pulmonary aspergillosis: clinical implications for antifungal therapy. J Infect Dis 2011; 203: 1324-32.
16. Marr KA, Boeckh M, Carter RA et al. Combination antifungal therapy for invasive aspergillosis. Clin Infect Dis 2004; 39: 797-802.
17. Mukherjee PK, Sheehan DJ, Hitchcock CA et al. Combination treatment of invasive fungal infections. Clin Microbiol Rev 2005; 18: 163-94.
18. Planche V, Ducroz S, Alanio A et al. In vitro combination of anidulafungin and voriconazole against intrinsically azole-susceptible and -resistant Aspergillus spp. Antimicrob Agents Chemother 2012; 56: 4500-3.
19. Petraitis V, Petraitiene R, Hope WW et al. Combination therapy in treatment of experimental pulmonary aspergillosis: in vitro and in vivo correlations of the concentration- and dose-dependent interactions between anidulafungin and voriconazole by Bliss independence drug interaction analysis. Antimicrob Agents Chemother 2009; 53: 2382-91.
20. Singh N, Limaye AP, Forrest G et al. Combination of voriconazole and caspofungin as primary therapy for invasive aspergillosis in solid organ transplant recipients: a prospective, multicenter, observational study. Transplantation 2006; 81: 320-6.
21. Seyedmousavi S, Brüggemann RJM, Melchers WJG et al. In vitro interaction of voriconazole combined with anidulafungin against triazole-resistant Aspergillus fumigatus by XTT assay. In: Abstracts of the Fifty-first Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, USA, 2011. Abstract M-493, p. 71. American Society for Microbiology, Washington, DC, USA.
22. Anidulafungin Plus Voriconazole Versus Voriconazole For The Treatment Of Invasive Aspergillosis. ClinicalTrials.gov Identifier:NCT00531479. http:// clinicaltrials.gov (29 August 2012, date last accessed).
23. Marr KA, Schlamm H, Rottinghaus ST et al. A randomised, doubleblind study of combination antifungal therapy with voriconazole and anidulafungin versus voriconazole monotherapy for primary treatment of invasive aspergillosis. In: Abstracts of the Twenty-second European Congress of Clinical Microbiology and Infectious Diseases, London, UK, 2012. Abstract LB 2812. European Society of Clinical Microbiology and Infectious Diseases, Basel, Switzerland.
24. Subcommittee on Antifungal Susceptibility Testing of the ESCMID European Committee for Antimicrobial Susceptibility Testing. EUCAST Technical Note on the method for the determination of broth dilution minimum inhibitory concentrations of antifungal agents for conidiaforming moulds. Clin Microbiol Infect 2008; 14: 982-4.
25. Meletiadis J, Mouton JW, Meis JF et al. Colorimetric assay for antifungal susceptibility testing of Aspergillus species. J Clin Microbiol 2001; 39: 3402-8.
26. Antachopoulos C, Meletiadis J, Sein T et al. Concentration-dependent effects of caspofungin on the metabolic activity of Aspergillus species. Antimicrob Agents Chemother 2007; 51: 881-7.
27. Mavridou E, Bruggemann RJ, Melchers WJ et al. Impact of cyp51A mutations on the pharmacokinetic and pharmacodynamic properties of voriconazole in a murine model of disseminated aspergillosis. Antimicrob Agents Chemother 2010; 54: 4758-64.
28. Seyedmousavi S, Brüggemann RJM, Melchers WJG et al. Pharmacodynamics of anidulafungin (AFG) against clinical Aspergillus fumigatus isolates in a non-neutropenic murine model of disseminated aspergillosis. In: Abstracts of the Fifty-second Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, USA, 2012. Abstract M-989, p. 108. American Society for Microbiology, Washington, DC, USA.
29. Seyedmousavi S, MelchersWJ, Verweij PE et al. Assessment of efficacy of antifungals in experimental models of invasive aspergillosis in an era of emerging resistance: the value of real-time quantitative PCR. Curr Opin Pharmacol 2011; 11: 486-93.
30. Prichard MN, Prichard LE, Shipman C Jr. Strategic design and three-dimensional analysis of antiviral drug combinations. Antimicrob Agents Chemother 1993; 37: 540-5.
31. Mouton JW, van Ogtrop ML, Andes D et al. Use of pharmacodynamic indices to predict efficacy of combination therapy in vivo. Antimicrob Agents Chemother 1999; 43: 2473-8.
32. Purkins L, Wood N, Greenhalgh K et al. Voriconazole, a novel wide-spectrum triazole: oral pharmacokinetics and safety. Br J Clin Pharmacol 2003; 56 Suppl 1: 10-6.
33. Patterson TF. Treatment of invasive aspergillosis: polyenes, echinocandins, or azoles?. Med Mycol 2006; 44: S357-62.
34. van de Sande WW, Mathot RA, ten Kate MT et al. Combination therapy of advanced invasive pulmonary aspergillosis in transiently neutropenic rats using human pharmacokinetic equivalent doses of voriconazole and anidulafungin. Antimicrob Agents Chemother 2009; 53: 2005-13.
35. Cuenca-Estrella M, Gomez-Lopez A, Garcia-Effron G et al. Combined activity in vitro of caspofungin, amphotericin B, and azole agents against itraconazole-resistant clinical isolates of Aspergillus fumigatus. Antimicrob Agents Chemother 2005; 49: 1232-5.
36. Shalit I, Shadkchan Y, Samra Z et al. In vitro synergy of caspofungin and itraconazole against Aspergillus spp.: MIC versus minimal effective concentration end points. Antimicrob Agents Chemother 2003; 47: 1416-8.
37. Philip A, Odabasi Z, Rodriguez J et al. In vitro synergy testing of anidulafungin with itraconazole, voriconazole, and amphotericin B against Aspergillus spp. and Fusarium spp. Antimicrob Agents Chemother 2005; 49: 3572-4.
38. Arikan S, Lozano-Chiu M, Paetznick V et al. In vitro synergy of caspofungin and amphotericin B against Aspergillus and Fusarium spp. Antimicrob Agents Chemother 2002; 46: 245-7.
39. Lewis RE, Kontoyiannis DP. Micafungin in combination with voriconazole in Aspergillus species: a pharmacodynamic approach for detection of combined antifungal activity in vitro. J Antimicrob Chemother 2005; 56: 887-92.
40. Perea S, Gonzalez G, Fothergill AW et al. In vitro interaction of caspofungin acetate with voriconazole against clinical isolates of Aspergillus spp. Antimicrob Agents Chemother 2002; 46: 3039-41.
41. Kirkpatrick WR, Perea S, Coco BJ et al. Efficacy of caspofungin alone and in combination with voriconazole in a guinea pig model of invasive aspergillosis. Antimicrob Agents Chemother 2002; 46: 2564-8.
42. Perkhofer S, Jost D, Dierich MP et al. Susceptibility testing of anidulafungin and voriconazole alone and in combination against conidia and hyphae of Aspergillus spp. under hypoxic conditions. Antimicrob Agents Chemother 2008; 52: 1873-5.
43. Kontoyiannis DP, Lewis RE. Combination chemotherapy for invasive fungal infections: what laboratory and clinical studies tell us so far. Drug Resist Updat 2003; 6: 257-69.
44. Johnson MD, MacDougall C, Ostrosky-Zeichner L et al. Combination antifungal therapy. Antimicrob Agents Chemother 2004; 48: 693-715.
45. Maertens J, Glasmacher A, Herbrecht R et al. Multicenter, noncomparative study of caspofungin in combination with other antifungals as salvage therapy in adults with invasive aspergillosis. Cancer 2006; 107: 2888-97.
46. Petraitis V, Petraitiene R, Sarafandi AA et al. Combination therapy in treatment of experimental pulmonary aspergillosis: synergistic interaction between an antifungal triazole and an echinocandin. J Infect Dis 2003; 187: 1834-43.